A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

NCT05572684 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors
Microsatellite Instability Low
Microsatellite Instability High
Microsatellite Stable
Ovarian Cancer
Gastric Cancer
Colo-rectal Cancer
Esophageal Cancer
Endometrial Cancer
Head Neck Cancer
Cervical Cancer
Lung Cancer

Interventions

DRUG: NC410
DRUG: pembrolizumab

Sponsor

NextCure, Inc.

Collaborators

[object Object]